Research Article Volume 01, Issue No. 02. 2024

The National Medical Journal of Health Science



Cardiovascular Adverse Effects of Phenylephrine Eyedrops

[1] Bagus, [1] Nugroho

[1] Faculty of Medicine, Sebelas Maret University, Surakarta City, Central Java, Indonesia

Correspondence : dr.bagus28749@gmail.com

Article History :

Received date : 2024/10/10
Revised date : 2024/11/17
Accepted date : 2024/12/28
Published date : 2025/01/02

Copyright: *© 2024 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (https://creativecommons.org/licenses/by-nc/4.0/).*

ABSTRACT

Background: The cardiovascular adverse effects of phenylephrine eyedrops have been a focal point in ophthalmological research, with a series of studies highlighting the implications of its use in diverse clinical scenarios. The literature indicates that patient comfort and systemic safety are paramount when considering phenylephrine administration. **Literature Review:** Further research revealed that even a 2.5% concentration of phenylephrine could provoke significant hypertensive responses, emphasizing the importance of monitoring systemic effects, particularly in patients with heightened susceptibility. This aligns with recommendations for applying pressure to the inner canthus post-administration to minimize systemic absorption, thereby mitigating potential adverse reactions. The intraoperative context was explored, who noted that intracameral phenylephrine, while beneficial during cataract surgeries, raises concerns about cardiovascular complications due to a lack of comparative data on adverse events. This gap in the literature necessitates further scrutiny of the safety profile of phenylephrine in surgical contexts. From a pharmacokinetic standpoint, documented severe cardiovascular events linked to high-dose phenylephrine, reinforcing the need for careful patient selection, especially among those with pre-existing cardiovascular conditions. This finding is crucial, as it highlights the systemic risks associated with phenylephrine, warranting cautious application in vulnerable populations. **Conclusion:** In conclusion, the body of literature surrounding the cardiovascular adverse effects of phenylephrine eyedrops underscores the necessity for cautious application in clinical practice. The studies collectively advocate for tailored dosing strategies, vigilant patient monitoring, and a comprehensive understanding of the systemic implications of phenylephrine, particularly in populations at risk for cardiovascular complications. This knowledge is essential for optimizing patient safety and therapeutic outcomes in ophthalmological care.

Keywords: Cardiovascular Adverse Effects, Phenylephrine Eyedrops

Downloaded from The National Medical Journal of Health Science
Copyright © International Medical Journal Corp. Ltd. All rights reserved

INTRODUCTION

The cardiovascular adverse effects of phenylephrine eyedrops have garnered significant attention in the ophthalmological literature, with a range of studies examining the implications of its use in various clinical contexts. The early study by (A Reinders & W McDougall, 1993) highlighted the importance of patient involvement in decisions regarding the use of REV-EYES, a medication that, while effective, can lead to discomfort and adverse reactions such as browache and hyperemia. Their findings indicated that a lower dose of phenylephrine was better tolerated by patients, suggesting a need for careful consideration of dosing to mitigate side effects.

Subsequent research by (Ayıntap et al., 2011) expanded on the cardiovascular implications of phenylephrine, revealing that even a 2.5% concentration could lead to significant hypertensive changes. This study emphasized the necessity of monitoring systemic effects, particularly in patients with smaller pupils, where the risk of adverse reactions could be heightened. Their recommendations for applying pressure to the inner canthus post-administration to reduce systemic absorption further underline the need for cautious use in susceptible populations.

(S. Williams et al., 2012) provided additional insights into the intraoperative use of intracameral phenylephrine, noting that while it serves as a beneficial adjunct in cataract surgeries, the potential for complications remains a point of concern. They acknowledged the lack of comparative data regarding the adverse events associated with its use, suggesting a gap in the literature that warrants further investigation.

(Farkouh et al., 2016) critically examined the systemic side effects of eye drops from a pharmacokinetic perspective, documenting severe cardiovascular events, including hypertension and arrhythmias, particularly with high-dose phenylephrine. Their findings highlighted the increased risks associated with

Downloaded from The National Medical Journal of Health Science
Copyright © International Medical Journal Corp. Ltd. All rights reserved

phenylephrine use in patients with pre-existing cardiovascular conditions, reinforcing the necessity for careful patient selection and monitoring.

In a more recent study, (Cheng et al., 2017) explored the impact of phenylephrine on the retinal vasculature, identifying its vasoconstrictive effects as a potential concern for retinal perfusion. This study added a layer of complexity to understanding the systemic implications of phenylephrine, as it suggested that the drug could adversely affect not just systemic blood pressure but also ocular perfusion, which is critical for maintaining retinal health.

(Jean Kremer et al., 2019) conducted a systematic review focused on the safety and efficacy of mydriatics in premature infants, emphasizing the need for rigorous assessment of adverse effects associated with phenylephrine. Their methodology provided a framework for evaluating the risk of bias in studies, underscoring the importance of evidence-based practice in pediatric ophthalmology.

Lastly, (Kazemi et al., 2021) investigated the effects of topical phenylephrine on episcleral venous pressure, finding unexpected results that may challenge established notions about the drug's effects on intraocular pressure dynamics. Their study raised questions about the mechanisms underlying the observed changes, suggesting that the interaction of phenylephrine with vascular structures may be more complex than previously understood.

Together, these studies illustrate a growing body of evidence regarding the cardiovascular adverse effects of phenylephrine eyedrops, highlighting the need for careful consideration in their clinical application. Each article contributes to a nuanced understanding of the potential risks associated with phenylephrine, advocating for a cautious approach to its use in vulnerable patient populations.

LITERATURE REVIEW

The article titled "Comparison of anti-mydriatic effects and patient comfort of the recommended and reduced doses of Rev-Eyes (0.5% dapiprazole HCL)" by

Downloaded from The National Medical Journal of Health Science
Copyright © International Medical Journal Corp. Ltd. All rights reserved

(A Reinders & W McDougall, 1993) presents an insightful examination of the effects of phenylephrine and its implications for patient comfort and side effects. The authors highlight the subjective experiences of patients in response to the drug, revealing a spectrum of opinions regarding the benefits and adverse effects associated with its use.

A notable aspect of the study is the contrasting experiences reported by subjects. Some patients expressed significant discomfort, including intense browaches and pronounced hyperemic reactions, which were not alleviated by common analgesics such as aspirin. This highlights a critical concern regarding the cardiovascular adverse effects of phenylephrine eyedrops, as such reactions can indicate a broader systemic response that may pose risks to patients, particularly those with pre-existing cardiovascular conditions.

The study's findings suggest that the reduced dose of Rev-Eyes was better tolerated than the full dose, with fewer reported side effects while maintaining efficacy in reversing dilation and cycloplegia, particularly in hyperopic patients. This is a significant observation, as it underscores the potential for optimizing dosing to enhance patient comfort without compromising therapeutic outcomes. The authors' conclusion that the half dose was equally effective in achieving desired clinical outcomes while minimizing discomfort is particularly relevant for clinical practice, suggesting a need for careful consideration of dosing strategies in the use of phenylephrine.

Moreover, the article raises important considerations for specific patient populations, such as those with narrow angles or shallow anterior chambers, who may require rapid reversal of dilation effects. The implications for these patients are critical, as the cardiovascular risks associated with phenylephrine could be exacerbated in individuals with anatomical predispositions that complicate dilation procedures.

The article "Effects of topical phenylephrine HCl 2.5% used before cataract surgery on systemic blood pressure" by (Ayıntap et al., 2011) provides significant insights into the cardiovascular effects of topical phenylephrine, particularly in the

Downloaded from The National Medical Journal of Health Science
Copyright © International Medical Journal Corp. Ltd. All rights reserved

context of cataract surgery. The authors conducted a study to evaluate the systemic blood pressure changes associated with the application of 2.5% phenylephrine eyedrops, a common practice aimed at facilitating surgical procedures by dilating the pupil.

The main findings of the study indicate that even at a concentration of 2.5%, phenylephrine can lead to significant hypertensive changes. This is an important observation given the widespread use of this medication in ophthalmic practices. The authors emphasize the necessity of caution when administering phenylephrine, especially in patients with pre-existing hypertension or cardiovascular concerns. They propose that the systemic effects of the drug can be mitigated by applying pressure to the inner canthus immediately after instillation, which may help reduce the absorption of the drug into the systemic circulation.

The statistical analysis presented in the article demonstrates a notable increase in systolic blood pressure following the administration of the eyedrops. This raises critical considerations for clinicians regarding the monitoring of blood pressure in patients receiving phenylephrine, particularly in surgical settings where patient stability is paramount. The authors advocate for a careful assessment of the risks and benefits when using this medication, especially in individuals who may be more susceptible to its hypertensive effects.

The article "The Short to Medium-Term Risks of Intracameral Phenylephrine" by (S. Williams et al., 2012) presents a thorough examination of the use of intracameral phenylephrine in the context of cataract surgery, particularly for patients with small pupil sizes. The authors articulate that phenylephrine serves as a beneficial adjunct during these procedures, enhancing pupil dilation and potentially mitigating the risks associated with small pupil complications.

One of the study's significant findings is the observation that the intraoperative and postoperative complication rates were nearly identical between groups that received intracameral phenylephrine and those that did not. This suggests that the addition of phenylephrine may effectively normalize the risk

Downloaded from The National Medical Journal of Health Science
Copyright © International Medical Journal Corp. Ltd. All rights reserved

typically associated with small pupil sizes during surgery. The authors contend that the comparable rates of complications imply that the intervention may have a protective effect, thus enhancing patient safety during cataract surgeries where pupil size is a concern.

However, the authors acknowledge a critical gap in the investigation: the absence of direct comparisons between eyes receiving intracameral phenylephrine and those that did not, specifically regarding potential adverse cardiovascular events. This omission raises questions about the safety profile of phenylephrine, particularly considering its known cardiovascular effects when administered systemically. Although the study did not report any intraoperative or postoperative complications attributable to phenylephrine, it remains unclear whether the complication rates could have been lower without its use. This uncertainty is particularly relevant given the established association between small pupil size and increased operative complications.

The retrospective design of the study is another limitation, as it may not fully account for confounding variables that could influence outcomes. The authors note that the selection of groups with similar preoperative risk factors strengthens their conclusions, yet the lack of data on pupil diameters before and after dilation limits the ability to draw definitive conclusions regarding the efficacy of the intervention.

The article "Systemic side effects of eye drops: a pharmacokinetic perspective" by (Farkouh et al., 2016) provides a comprehensive examination of the cardiovascular adverse effects associated with the use of phenylephrine eyedrops, particularly in the context of their vasoactive properties. The authors highlight that while phenylephrine is a common agent used for pupil dilation and the treatment of noninfectious conjunctivitis, its systemic absorption can lead to significant cardiovascular complications.

A critical evaluation of the material reveals that the authors effectively document instances of severe cardiovascular events, including acute increases in

Downloaded from The National Medical Journal of Health Science
Copyright © International Medical Journal Corp. Ltd. All rights reserved

blood pressure, cardiac arrhythmias, and even myocardial infarction, particularly following the administration of high-dose phenylephrine eyedrops. This evidence underscores the importance of dosage consideration in clinical practice. The article suggests that the risk of these adverse effects is markedly reduced when lower concentrations of the active substance are utilized, which is a crucial insight for practitioners prescribing such treatments.

Moreover, the article emphasizes the need for caution in specific patient populations, including those with pre-existing conditions such as hypertension, aneurysms, tachycardia, or other cardiac diseases. This recommendation is particularly relevant given the potential for systemic toxicity, especially in vulnerable groups like children and the elderly. The authors advocate against the use of a 10% phenylephrine solution in these populations, thereby highlighting a critical aspect of patient safety that should guide clinical decision-making.

The article "Phenylephrine Affects Peripapillary Retinal Vasculature—an Optic Coherence Tomography Angiography Study" by (Cheng et al., 2017) provides a critical examination of the effects of phenylephrine, a commonly used mydriatic agent, on the retinal vasculature. The authors focus on the physiological implications of phenylephrine, particularly its role as an α1-adrenergic receptor agonist that induces vasoconstriction in peripheral vessels, which includes the conjunctival vessels and anterior ciliary arteries.

The study's primary hypothesis—that phenylephrine reduces retinal perfusion—was investigated through the use of optical coherence tomography angiography (OCTA). This methodology is noteworthy as it allows for real-time imaging and assessment of blood flow within the retinal vasculature, offering insights into the hemodynamic changes induced by phenylephrine. The findings indicate a significant reduction in blood velocity at the optic nerve head, suggesting that even topical application of phenylephrine can have pronounced effects on ocular blood flow.

Downloaded from The National Medical Journal of Health Science
Copyright © International Medical Journal Corp. Ltd. All rights reserved

One of the critical evaluations presented in the article is the differential response of retinal vessels to hypoxia, which underscores the complex interplay between vasoconstriction induced by phenylephrine and the subsequent effects on retinal perfusion. The authors emphasize the necessity of understanding these dynamics, particularly in the context of patients who may have pre-existing vascular conditions or those undergoing intraocular surgery.

Moreover, the implications of reduced retinal perfusion are profound, as they could potentially lead to adverse cardiovascular effects, especially in susceptible populations. The study highlights the importance of careful consideration when using phenylephrine in clinical practice, particularly in individuals with underlying cardiovascular risks.

The article "Systematic review of mydriatics used for screening of retinopathy in premature infants" by (Jean Kremer et al., 2019) provides a comprehensive examination of the safety and efficacy of mydriatic agents, specifically focusing on phenylephrine, in the context of screening for retinopathy in premature infants. The authors conducted a systematic literature search across multiple databases, ensuring a robust collection of relevant studies from 2017 and 2018. By employing keywords such as "phenylephrine," "adverse effects," and "eye drops," they aimed to gather data on both the efficacy of pupil dilation and the safety profile regarding cardiovascular outcomes.

One of the critical strengths of this review is its methodological rigor in screening and eligibility assessment. The independent evaluation of studies enhances the reliability of the findings, particularly in a vulnerable population like premature infants. The article effectively collates data on blood pressure and heart rate, which are crucial indicators of cardiovascular health, thereby directly addressing the potential adverse effects of phenylephrine eyedrops. This focus on cardiovascular outcomes is particularly relevant given the known sympathomimetic effects of phenylephrine, which can lead to increased blood pressure and heart rate, raising concerns about its safety in this delicate demographic.

Downloaded from The National Medical Journal of Health Science
Copyright © International Medical Journal Corp. Ltd. All rights reserved

However, while the review successfully identifies and summarizes relevant studies, it could benefit from a more detailed discussion of the clinical implications of the findings. For instance, the authors could elaborate on the thresholds for adverse cardiovascular effects that would warrant caution in administering phenylephrine to premature infants. Additionally, a more thorough exploration of the variability in individual responses to phenylephrine, influenced by factors such as gestational age and underlying health conditions, would provide a deeper understanding of its safety profile.

Moreover, the review highlights the importance of monitoring cardiovascular parameters in studies involving mydriatic agents. The extraction of information regarding trial participant characteristics and intervention types is commendable, but the review could enhance its critical evaluation by discussing how these factors may influence the outcomes observed in the included studies.

The article "Effect of Topical Phenylephrine 2.5% on Episcleral Venous Pressure in Normal Human Eyes" by (Kazemi et al., 2021) delves into the intricate relationship between topical phenylephrine and episcleral venous pressure (EVP) in human eyes. The authors present a well-structured study that highlights the complexities of EVP regulation and the unpredictable nature of vasoactive compounds, particularly sympathomimetics like phenylephrine.

One of the key insights from the article is the authors' observation that the application of phenylephrine resulted in a decrease in EVP 60 minutes post-instillation. This finding aligns with the expected pharmacological action of phenylephrine as a vasoconstrictor, primarily acting on alpha-1 adrenergic receptors in vascular smooth muscle. However, the authors note an intriguing contradiction; while a decrease in EVP was anticipated due to the expected vasoconstriction of episcleral veins, the mechanism appears to be more nuanced. The study suggests that the reduction in EVP may be mediated by the constriction and dilation of the episcleral arteriovenous anastomoses (AVAs), rather than a straightforward decrease in vein diameter.

Downloaded from The National Medical Journal of Health Science
Copyright © International Medical Journal Corp. Ltd. All rights reserved

The article further explores the potential mechanisms for intraocular pressure (IOP) elevation observed in some subjects, positing that this could be related to the release of iris pigment following pharmacological pupillary dilation. This pigment may accumulate in the trabecular meshwork, thereby decreasing outflow facility. However, the authors acknowledge that the literature presents inconclusive evidence regarding phenylephrine's effect on IOP, indicating a need for further investigation.

Kazemi et al. (2021) effectively illustrate the multifaceted interactions between topical phenylephrine and ocular hemodynamics. Their findings contribute to the understanding of the cardiovascular implications of phenylephrine eyedrops, particularly concerning its vasoactive properties. The study emphasizes the necessity for clinicians to consider the systemic absorption and potential contralateral effects of topical medications, as these factors may complicate the expected outcomes of treatment.

CONCLUSION

The cardiovascular adverse effects of phenylephrine eyedrops have been a focal point in ophthalmological research, with a series of studies highlighting the implications of its use in diverse clinical scenarios. The literature indicates that patient comfort and systemic safety are paramount when considering phenylephrine administration. Early investigations underscored the necessity of involving patients in treatment decisions due to the discomfort associated with phenylephrine, including browache and hyperemia. Their findings suggest that lower doses may enhance tolerability while maintaining efficacy, thus advocating for careful dosing strategies.

Further research revealed that even a 2.5% concentration of phenylephrine could provoke significant hypertensive responses, emphasizing the importance of monitoring systemic effects, particularly in patients with heightened susceptibility. This aligns with recommendations for applying pressure to the inner canthus post-administration to minimize systemic absorption, thereby mitigating potential adverse reactions.

Downloaded from The National Medical Journal of Health Science
Copyright © International Medical Journal Corp. Ltd. All rights reserved

The intraoperative context was explored, who noted that intracameral phenylephrine, while beneficial during cataract surgeries, raises concerns about cardiovascular complications due to a lack of comparative data on adverse events. This gap in the literature necessitates further scrutiny of the safety profile of phenylephrine in surgical contexts.

From a pharmacokinetic standpoint, documented severe cardiovascular events linked to high-dose phenylephrine, reinforcing the need for careful patient selection, especially among those with pre-existing cardiovascular conditions. This finding is crucial, as it highlights the systemic risks associated with phenylephrine, warranting cautious application in vulnerable populations.

Recent studies have expanded the understanding of phenylephrine's effects on retinal vasculature, indicating potential implications for ocular perfusion and systemic blood pressure. This complexity underscores the multifaceted nature of phenylephrine's action and its impact on both systemic and ocular health.

A systematic review further emphasized the necessity of rigorous assessment of adverse effects in specific populations, particularly premature infants, where the cardiovascular implications of mydriatics are of particular concern. The review highlighted the importance of evidence-based practices in pediatric ophthalmology, advocating for thorough evaluations of safety profiles.

Lastly, the study challenged existing notions regarding the effects of phenylephrine on episcleral venous pressure, suggesting a more complex interaction with vascular structures than previously understood. This finding calls for additional research to elucidate the mechanisms at play and their potential cardiovascular implications.

In conclusion, the body of literature surrounding the cardiovascular adverse effects of phenylephrine eyedrops underscores the necessity for cautious application in clinical practice. The studies collectively advocate for tailored dosing strategies, vigilant patient monitoring, and a comprehensive understanding of the systemic implications of phenylephrine, particularly in populations at risk for

Downloaded from The National Medical Journal of Health Science
Copyright © International Medical Journal Corp. Ltd. All rights reserved

cardiovascular complications. This knowledge is essential for optimizing patient safety and therapeutic outcomes in ophthalmological care.

DISCLOSURE STATEMENT

- Disclosure Statement : The authors have no conflicts of Interest to declare
- Funding Sources : None
- Acknowledgements : -
- Author Contribution : All authors discussed and contributed the final content for journal submission and publication

REFERENCES

1. A Reinders, D. & W McDougall, B., 1993. Comparison of anti-mydriatic effects and patient comfort fo the recommended and reduced doses of Rev-Eyes (0.5% dapiprazole HCL). [PDF]
2. Ayıntap, E., Keskin, U., Çoşkun, M., İlhan, Özgür, Semiz, H., & Öksüz, H., 2011. Effects of topical phenylephrine HCl 2.5% used before cataract surgery on systemic blood pressure. [PDF]
3. S. Williams, G., Radwan, M., Kadare, S., & P. R. Williams, C., 2012. The Short to Medium-Term Risks of Intracameral Phenylephrine. ncbi.nlm.nih.gov
4. Farkouh, A., Frigo, P., & Czejka, M., 2016. Systemic side effects of eye drops: a pharmacokinetic perspective. ncbi.nlm.nih.gov
5. Cheng, J., Yu, J., Jiang, C., & Sun, X., 2017. Phenylephrine Affects Peripapillary Retinal Vasculature—an Optic Coherence Tomography Angiography Study. ncbi.nlm.nih.gov
6. Jean Kremer, L., M Reith, D., Medlicott, N., & Broadbent, R., 2019. Systematic review of mydriatics used for screening of retinopathy in premature infants. ncbi.nlm.nih.gov
7. Kazemi, A., W. McLaren, J., & J. Sit, A., 2021. Effect of Topical Phenylephrine 2.5% on Episcleral Venous Pressure in Normal Human Eyes. ncbi.nlm.nih.gov

Downloaded from The National Medical Journal of Health Science
Copyright © International Medical Journal Corp. Ltd. All rights reserved